This review covers the synthesis of various cyclic peptide natural products possessing highly functionalized tryptophan residues, focusing on the examples of diazonamide A, the TMC-95 compounds, the celogentin/moroidin family and the complestatin/chloropeptin system. Recent efforts toward the preparation of these modified-tryptophan-containing peptides will be outlined, focusing primarily on the novel methods for the assembly of the highly functionalized indole/tryptophan moieties at the core of these structures.
Highly functionalized cyclic peptide natural products are increasingly being used as therapeutic agents. Vancomycin, a powerful antibiotic and pioneer of such therapeutic cyclic peptides, has been in clinical use for several decades, as has cyclosporin, an immunosuppressant cyclic peptide used to prevent rejection following organ transplants. More recently, semi-synthetic analogues of the echinocandin class of cyclic peptides have been approved for use as antifungal agents.
Many cyclic peptide natural products possessing potent biological activity contain highly functionalized tryptophan residues. Examples include the diazonamides, TMC-95 compounds, celogentins and complestatin/chloropeptin (Figure 1 ). These peptides are extensively modified through incorporation of oxygen functionality into the amino acid residues and/or oxidative cross-linking of the indole group of the tryptophan side chain. In the above examples, the TMC-95 compounds contain a modified tryptophan residue which has been oxidized to an oxindole-diol as well as cross-linked to the 3'-position of a tyrosine residue. The tryptophan indole group of the complestatin/chloropeptin and celogentin/moroidin compounds is oxidatively cross-linked to phenylglycine and histidine residues, respectively, to generate biaryl-linkages. In the celogentins the indole group is further coupled to a leucine side chain through an aryl-alkyl linkage. The modified tryptophan core of diazonamide A is doubly cross-linked to a tyrosine residue to form the central tetracycle, which is further cross-linked to the chloroindole group derived from a second highlymodified tryptophan residue.
Recent efforts toward the preparation of these modified-tryptophan-containing peptides will be outlined in this review, focusing primarily on the novel methods for the preparation of the highly functionalized indole moieties at the core of these structures.
Diazonamide A
Diazonamides A-D were originally isolated in 1991 by Fenical and co-workers [1] , and were shown to possess cytotoxicity against several human cancer cell lines. Diazonamide A possesses potent antimitotic activity, causing treated cells to lose both interphase and spindle microtubules. The inhibition of microtubule assembly is accompanied by potent inhibition of tubulin-dependent GTP hydrolysis, but diazonamide A does not bind to the vinca alkaloid or dolostatin binding sites [2] . Synthesis of the originally proposed structure was completed by Harran in 2001 [3] , but this material was not the natural product. Harran proposed a revised structure for diazonamide A [4] , which was subsequently shown to be correct through total syntheses completed by his group [5] and that of Nicoloau [6, 7] . The central core of the diazonamides was therefore revealed to comprise a highly modified tryptophan moiety.
Nicolaou's synthesis of diazonamide A starts with the preparation of the core functionalized tryptophan skeleton. Nucleophilic addition of the dianion of Val-Ser-derived oxazole 1 to 7-bromoisatin derivative 2 generates oxindole 3 containing a tertiary alcohol (Scheme 1). Treatment of tertiary benzylic alcohol 3 with a protected tyrosine under acidic conditions then generates oxindole 4 containing the critical quaternary centre of diazonamide, through a Friedel-Crafts alkylation-type process. Macrolactamization and protecting group manipulation then gives macrocycle 5 which is coupled to the second indole group to give 6. Formation of the second oxazole is then followed by a Witkop-type photo-induced biaryl coupling-as employed by Harran in the synthesis of the originally proposed diazonamide structure-to generate the second macrocycle 7 in 33% yield. Chlorination is then followed by reduction of the oxindole to the aminal which cyclizes to generate furanoid ring 8. Finally, deprotection and coupling of isovaleric acid completes the total synthesis of the natural product (Scheme 1) [6].
Harran's synthesis of diazonamide A also starts with the construction of the core tryptophan moiety. Racemic 7-bromotryptophan derivative 11 is generated from 7-bromoindole 10 and bromopyruvate oxime 9, and is then coupled to Z-Val with subsequent oxidative cyclization generating oxazolylindole 12 (Scheme 2). Coupling of a tyrosine residue to give 13 followed by oxidative macrocyclization generates the macrocycle 14 incorporating the quaternary centre and furanoid ring a single step (in 25% yield). Coupling of the second indole moiety and formation of the second oxazole through oxidation/cyclodehydration then generates intermediate 16, closely related to that of Nicolaou (6), but containing additional 7-oxygen functionality on the second indole ring. Photo-induced Witkoptype reaction of the corresponding phenoxide leads to biaryl coupling/macrocyclization with much greater efficiency than previous examples (72% yield) as a result of the higher electron density on the donor ring. With the 7-oxygen substituent having served its purpose, deoxygenation of 17 to give 18 is then accomplished through hydrogenolysis of the corresponding triflate, with chlorination and coupling of isovaleric acid then completing the total synthesis of diazonamide (Scheme 2) [5] .
In both syntheses by Harran and Nicolaou, similar methods are used to construct the key parts of the diazonamide A structure. Both use a photo-induced Witkop-type reaction to generate the biaryl linkage, and related oxidative-and nucleophilic-couplings between a tyrosine residue and an indole or isatin moiety are used to generate the central quaternary carbon. Both syntheses are of similar length (20 vs. 22 steps in longest linear sequence), though the Harran synthesis proceeds in a significantly higher overall yield (0.9 vs. 0.02% yield). Shortly after reporting the first synthesis of diazonamide A, Nicolaou reported a second approach to the natural product in which the major improvement was generation of the critical biaryl linkage through a Suzuki coupling [7] . In the improved synthesis the order of assembly of the subunits was changed so that bromoisatin 19 was initially coupled with a protected tyrosine residue to give tertiary alcohol 20, which was modified to indoline 21. Suzuki coupling with oxazolyl-indole-4- boronate 23, generated from 4-bromoindole 22, then generated the key biaryl linkage at an early stage. Further modification gave aldehyde-oxime ether 24 which underwent a heteropinacol coupling/macrocyclization upon treatment with samarium iodide to construct the right-hand macrocycle 25 containing the highly functionalized tryptophan core. The aminoalcohol functionality was then elegantly elaborated to the second oxazole moiety in 26. Macrolactamization then generated the left-hand macrocycle 27 with subsequent manipulations similar to the original synthesis enabling preparation of the natural product (Scheme 3). The overall length of this second generation synthesis (33 steps) is longer than the first, but the yield is similar (0.014%). More importantly, it provides a complementary approach to the first Nicolaou and Harran syntheses with the central modified tryptophan generated at a late rather than early stage. 
TMC-95A-D
TMC-95A and diastereomers TMC-95B-D were isolated from Apoispora montagnei and exhibit potent selective proteasome inhibition [9] . Such proteasome inhibitors have potential application against a number of disorders including cancer and immune diseases. The key structural feature of the TMC compounds is the presence of a highly oxidized tryptophan core, linked through a biaryl bond to C3 of a tyrosine residue.
Initial model studies toward the dihydroxyoxindole core were reported by Ma [10] soon after the structures of the natural products were revealed. Ma's approach starts with 7-bromoisatin 19 which is converted to 7-bromooxindole 30 and then coupled to Garner's aldehyde 31 to give the dehydrotryptophan skeleton 32 with low E/Z-selectivity (Scheme 5). Dihydroxylation of the E-olefin with OsO 4 /pyridine gave dihydroxyoxindole 33 with high diastereoselectivity; however, attempted Suzuki coupling with a tyrosine-3-boronic acid was not effective [11] . In summary, all approaches to the synthesis of the TMC-compounds employ similar strategies; Suzuki couplings have been used by all groups to generate the biaryl linkage, olefination of 6-halo-isatin or 6halo-oxindole is the general method to construct the core tryptophan skeleton, with dihydroxylation of the exo-double bond then generating the key diol functionality. While Ma, Danishefsky and Williams all used an OsO 4 -catalyzed dihydroxylation approach (with varying substrate-or auxiliary-directed stereocontrol), Harama/Inoue used an epoxidation/ring opening strategy to generate the diol. Future combinations of these strategies may allow preparation of the remaining stereoisomers, TMC-95C/D. Two strategies were employed to install the cis-propenylamide: anti-decarboxylative elimination of allo-threonine (Inoue/Harama, Williams) or rearrangement-desilyation of a silylallylamide (Danishefsky).
Complestatin/Chloropeptin I
Complestatin (also known as chloropeptin II) and chloropeptin I were independently isolated from Streptomyces species [17, 18] and shown to possess potent anti-HIV activity through disruption of binding of HIV gp-120 glycoprotein to the CD4 receptor of T-lymphocytes [19] . These bicyclic peptides are closely related to kistamycin and less closely to the vancomycin family of cyclic peptide antibiotics. Complestatin and chloropeptin I differ only in the position of the biaryl linkage between the hydroxyphenylglycine and tryptophan residues (phenol C3 to indole C6 in complestatin and indole C7 in chloropeptin I, Figure 1 ). Interestingly, complestatin can be converted to chloropeptin I with complete retention of axial chirality upon exposure to strongly acidic conditions [20] .
The key steps required in the preparation of chloropeptin I and complestatin are the generation of the biaryl linkage and macrocyclization. Several model studies [21] have been undertaken, with Stille and Suzuki couplings being the most common methods used for biaryl coupling, employing all permutations of aryl halide and arylstannane/arylboronic acid precursors. Preparation of the biaryl-containing macrocycle of complestatin has proved most elusive, with model studies by Gurjar [21a] and Roussi [21b] initially suggesting Suzuki coupling and macrolactamization would not provide efficient routes to the 17-membered macrocycle of the natural product, though nickel(0)mediated reductive cyclization of a linear bromophenol-bromoindole did proceed in low yield. Rich [22] reported the first efficient synthesis of the biaryl-containing macrocycle of complestatin, employing Suzuki coupling to form the biaryl linkage. The requisite 6-bromotryptophan 64 was prepared by ene-reaction of 6-bromo-3-methyleneindoline 63 with ethyl glyoxylate N-tosylimine. Suzuki coupling with phenylglycine-3-boronate 65 gave the biaryl-linked product 66 in good yield. Macrocyclization was effected with FDPP to give 67 in 43% yield. Switching the order of the steps was also effective. Deprotection of 64 and 65 and subsequent peptide coupling gave tripeptide 68 which underwent intramolecular Suzuki coupling/ macrocyclization to give 67 in 56% yield (Scheme 11). The success of these macrocyclizations in spite of the failure of model studies suggests that such cyclizations are very susceptible to substituent effects around the ring and that additional substituents in the fully-functionalized system result in conformational restriction which predisposes the system to ring-closure. Treatment of macrocycle 67 with 50% TFA effected rearrangement to the indole C7-linked isomer, equivalent to that seen for conversion of complestatin to chloropeptin I. The total synthesis of chloropeptin I has been reported by Hoveyda [23] . Formation of the left-hand ring was effected through intramolecular Cu(II)catalyzed coupling of the phenylalanyl-4-boronic acid and 3-hydroxyphenylglycine residues in tripeptide 69 to generate the biaryl ether linkage of macrocycle 70 (Scheme 12). Iodination at the 5'-position of the phenylglycine residue and coupling of 7-stannyltryptophan 71 gave hexapeptide 73, which underwent intramolecular Stille coupling/ macrocyclization to generate the bicyclic compound 74. The requisite 7-stannyltryptophan derivative 71 was prepared from the corresponding 7-hydroxytryptophan 72 through stannylation of the corresponding triflate. Interestingly, the intramolecular Stille coupling generated the righthand macrocycle as a single atropisomer with the same configuration as that found in the natural product.
In 2001 Singh and co-workers [19] disclosed the isolation of "isocomplestatin"-reportedly an atropisomer of natural complestatin-together with complestatins A and B (oxidized complestatins containing oxindole and hydroxyoxindole moieties, respectively). Hoveyda set out to prepare both atropisomers of the complestatin structure. Initially the biaryl-containing right-hand ring of complestatin was prepared through intramolecular Suzuki coupling/macrocyclization of tripeptide 78 (Scheme 13) [24] . Hoveyda prepared the requisite tryptophan-6-boronate 77 from known hydroxytryptophan derivative 75 via the triflate 76. In the model macrocyclization study a mixture of atropisomers 79a and 79b was formed, corresponding to the righthand macrocycles of complestatin and its atropisomer. Acid treatment of each atropisomer resulted in rearrangement-with retention of configuration about the biaryl axis-to the C7-linked macrocycles corresponding to those in chloropeptin I and its atropisomer. This strategy is closely related to the model studies performed by Rich (Scheme 11), with the boronate and halide moieties required for the Suzuki macrocyclization switched. Unfortunately no discussion of the atropselectivity of the macrocyclization is made in the Rich report so the two approaches cannot be compared in this regard.
When Hoveyda extended this methodology to generation of the bicyclic system, the intramolecular Suzuki coupling of 80 gave only one atropisomer of product 81, being different to that found in complestatin (Scheme 14). Hoveyda also showed that the compound so labeled as isocomplestatin by Singh [19] was in fact the same as complestatin. Ultimately, Hoveyda had completed the synthesis of isocomplestatin, the atropisomer of complestatin. Attempts to convert isocomplestatin to the natural product, complestatin, resulted only in decomposition, and a total synthesis of complestatin is therefore yet to be realized.
Celogentins
The celogentins are a family of bicyclic peptidebased natural products that contain a highly functionalized central tryptophan residue. The first member of the family isolated was moroidin, the structure of which was determined by Dudley Williams and collaborators [25] . The Kobayashi group [26] then isolated a series of related peptides, named celogentins A-K, between 2003-2005. The celogentins, as well as moroidin, were isolated from seeds of the cockscomb plant, Celosia argentea, and have been shown to bind to tubulin and possess potent anti-mitotic activity [27] . Comber and Moody [28] reported the first studies towards preparing the Trp-His linkage present in the celogentin/moroidin family, employing a nucleophilic aromatic substitution of 2-chloro-3formylindole 82 to generate 2-histidinylindole 84 (Scheme 15). Histidinol derivative 83 was used to avoid racemization, and Horner-Wadsworth-Emmons olefination of the formyl group with glycine phosphonate 85 generated the (Z)-dehydrotryptophan moiety 86 [29] . Asymmetric hydrogenation with Rh(I)-(R,R)-DIPAMP then gave the 2'-substituted tryptophan 87 in 70% de. The Trp-His moiety was then elaborated to the right hand ring of moroidin 88 via standard peptide coupling and macrocyclization methods (Scheme 15).
Castle [30] has also developed a route to the righthand ring of a member of the moroidin/celogentin family, namely celogentin C. A novel NCS-promoted oxidative coupling of tryptophan-and histidinecontaining dipeptides 89 and 90 generated the key Trp-His linkage of 91 in a remarkably simple operation. Removal of protecting groups and macrolactamization then gave the macrocycle 92 (Scheme 16). In model studies toward the left-hand ring, Castle has reported the preparation of a 2,6-disubstituted tryptophan using Larock's annulation methodology [31] . Asymmetric alkylation of glycine imine 93 with bromide 94 gave the propargylglycine derivative 95, which was converted to the Cbz-protected derivative 96. Larock annulation with iodoaniline 97 using Cook's conditions [32] gave 2,6-disubstituted tryptophan 98 (Scheme 17). We have also used a related Larock annulation to generate 2,6-disubstituted tryptophan derivative 104 [33] . 4-Iodo-3-nitrobenzaldehyde 99 was converted to cinnamate 100, which was reduced to iodoaniline 101. Introduction of an oxazolidinone auxiliary gave 102, which was followed by Larock annulation with Schollkopf propargylglycine 103 [32] Very recently Moody and Bentley [34] have prepared stephanotic acid [35] methyl ester 110, essentially containing the same macrocycle as the left-hand ring of the moroidin/celogentin family. Indole-6-isopropyl ketone 105 was converted to a mixture of all four stereoisomers of β-indol-6-ylleucine 106 through a four-step procedure (Scheme 19). Separation into racemic diastereomers was followed by formylation and coupling of an isoleucine residue to give dipeptide 107. Further separation of diastereomers was followed by Horner-Wadsworth-Emmons olefination to give dehydrotryptophan-containing peptide 108. Asymmetric hydrogenation proceeded with high stereoselectivity, but macrocyclization to With routes to both the left-and right-hand macrocycles of members of the moroidin/celogentin family now completed, future combination of these methods should allow for total synthesis of the natural products.
In summary, many varied approaches to the highly functionalized tryptophan residues present in these complex cyclic peptide alkaloids have been accomplished. Elaboration of substituted indoles (or oxindoles/isatin derivatives) to tryptophan derivatives through olefination and subsequent hydrogenation or dihydroxylation remains a common strategy, as does Larock annulation of iodoaniline derivatives. Other strategies such as ene-reactions, alkylations, and direct side-chain functionalization of commercially available protected tryptophan derivatives are less common but equally effective.
The biaryl linkages so prevalent in these peptides (especially to tyrosine residues) are commonly prepared using Suzuki and Stille cross-couplings, though Suzuki couplings are employed much more frequently and appear to be more general.
